ClinicalTrials.gg
RecruitingNCT07630376Updated Sep 11, 2026

Evaluating a Workbook to Promote Autistic Wellbeing

An interventional study of Guided self-help workbook for autistic adults in Autism and Wellbeing, sponsored by Canterbury Christ Church University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Canterbury Christ Church University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Autistic Disorder with a site in United Kingdom — 10 open to participants now, 14 under way, none of them phase 3. Autistic Disorder · United Kingdom.

Planned enrollment
19th of 21
10 · median 69
Started
2026
with 2 others
No phase
19 of 37
6 open now
Primary completion
2027-03
later than 12 of 13 live
Registered
35th of 37
by date
Lead sponsor
1 of 37
Canterbury Christ Church University

Among the 37 studies in Autistic Disorder with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 19 with no phase, reaches primary completion later than 12 of the 13 other live ones, and was the 35th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

10 of the 37 studies in Autistic Disorder with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Autistic Disorder with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the feasibility and acceptability of a brief guided self-help wellbeing intervention for autistic adults accessing UK secondary mental health services. The study also aims to begin to evaluate whether use of the workbook is associated with any changes in wellbeing. The main questions it aims to answer are:

  1. Is it feasible to recruit and retain autistic adults to participate in the study?
  2. Do participants find the workbook acceptable and relevant?
  3. Are there measurable improvements in wellbeing following workbook use?
  4. What changes, if any, do participants recommend for future versions of the intervention?

Participants will:

  • Take part in 4-6 sessions of 30-60 minutes using the guided self-help workbook with the support of a trained National Health Service support worker, assistant psychologist, or mental health professional
  • Complete wellbeing questionnaires before, during, and after using the workbook
  • Complete brief daily wellbeing ratings throughout the study
  • Take part in a 1:1 semi-structured interview of up to an hour to discuss their experience of the workbook
Read the detailed description

Autism is a lifelong neurodevelopmental difference that affects how people communicate, experience the world, and relate to others. In the UK, more than 1% of people are estimated to be autistic, with rates of diagnosis rapidly increasing. Many autistic adults experience mental health challenges such as anxiety, depression, and suicidal thoughts. Some may experience 'autistic burnout', a state of deep exhaustion and loss of coping ability. These difficulties can result from long-term stress, 'masking' (hiding autistic traits to fit in), and lack of understanding or support.

In the UK National Health Service, post-diagnostic support for autistic adults is limited, often consisting only of information or signposting. While existing psychological therapies can help with anxiety and depression, they are not always designed with the needs of autistic people in mind. This highlights a clear need for preventative, accessible, and autism-specific wellbeing support, especially within the National Health Service, where demand is high and resources are limited.

This study aims to explore whether a new guided self-help wellbeing workbook designed specifically for autistic adults is feasible and acceptable, and to get an initial impression of its helpfulness in improving wellbeing. It focuses on helping people to understand autism and manage their energy levels using 'energy accounting' (Toudal \& Attwood, 2024), and to plan for wellbeing using personalised strategies. The aim is to help autistic adults improve self-understanding, communicate their needs, and enhance wellbeing in everyday life.

The study will have three phases (baseline: a 1-2 week period prior to completing the workbook; intervention: a 4-6 week period during completion of the workbook; follow-up: a 3-4 week period following workbook completion). Participants will be asked to complete standardised questionnaires at the beginning and end of each phase. Brief daily wellbeing ratings will be collected throughout all three phases. Finally, an interview of up to an hour will be conducted with participants at the end of the follow-up phase.

There are six primary indicators which will be compared against pre-specified progression criteria. The primary outcomes are 1) ease of recruitment to the study; 2) participant retention in the intervention; 3) participant retention in the study; 4) intervention acceptability; 5) outcome measure completion; 6) whether there is a preliminary indicator of efficacy on the primary outcome measure (wellbeing). Progression criteria will be used to help decide whether the research should progress to more powered intervention studies in future.

03

Conditions studied

  • Autism
  • Wellbeing

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A pre-existing diagnosis of autism OR on a waiting list for autism assessment OR self-identified as autistic and scoring above cut-off on the autism quotient (AQ-50) screening questionnaire.
  • Aged 18 years or over and able to give to participate.
  • Under the care of a community-based mental health team in Kent and Medway Mental Health NHS Trust and not due for discharge during the study period.
  • Have already completed assessment processes (including risk assessment) during intake by the clinical team and a management plan is in place.
  • The named clinician assesses that the individual is in sufficiently stable condition to participate in the study, and is likely to remain engaged in the intervention.
  • Proficiency in reading and writing English.
  • If on medication for mental health, the dose is stable (minimum of 3 months) with no planned changes during the study.

Exclusion criteria

Exclusion Criteria:

  • Presence of a moderate to severe learning disability that would limit independent engagement with self-help materials.
  • Engaged in another psychological therapy or psychologically-informed intervention, or due to begin another during the study.
  • Current acute mental health crisis or elevated risk to self/others requiring intensive intervention (assessed via clinical team judgement).
  • Insufficient capacity to engage with the study protocol or complete measures (as determined by the care team).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Guided self-help workbook for autistic adults

    Within-subjects comparison

    Behavioral: Guided self-help workbook for autistic adults

Interventions

  • BehavioralGuided self-help workbook for autistic adults

    The workbook's components are: psycho-education and energy accounting (Toudal \& Attwood, 2024) - including sensory awareness - and planning for wellbeing. It will be delivered over four to six sessions of between 30-60 minutes each with a trained National Health Service support worker, assistant psychologist, or mental health professional. Sessions would be conducted in-person, via telephone, or via video.

06

What researchers measure

Primary outcomes

  1. Number of participants recruited to the study

    The number of participants recruited over 6 months will be compared against the following progression criterion to assess the feasibility of recruitment: Green: 8-10; Amber: 6-7; Red: \<5

    Time frame: 6 months following start of recruitment

  2. Proportion of participants who complete the guided self-help intervention

    The proportion of participants who complete the guided self-help intervention will be compared against the following progression criterion to assess retention in the intervention: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Weeks 2-8

  3. Proportion of participants who remain in the study

    The proportion of study participants who remain in the study will be compared against the following progression criterion to assess retention in the study: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Weeks 0-12

  4. Guided self-help intervention acceptability

    Response to Likert type questions and thematic analysis of qualitative data will be compared against the following progression criterion to assess retention in the study: Green: the majority of participants report the intervention is acceptable as it is or with minor adjustments; Amber: there are inconsistent reports of acceptability or the intervention requires bigger adjustments; Red: the majority of participants report the intervention is unacceptable or requires adjustments which cannot be completed

    Time frame: Weeks 11-12

  5. Completion rate of outcome measures

    The rate of the outcome measures completion will be compared against the following progression criterion to assess the feasibility of outcome measurement: Green: ≥75%; Amber ≥50%; Red: \<50%

    Time frame: Weeks 0-12

  6. Proportion of participants showing reliable improvement on the ReQoL-20 from baseline (weeks 0-1) to post-intervention (weeks 7-8)

    The ReQoL-20 contains 20 items measuring quality of life, with higher scores indicating greater quality of life. The proportion of participants showing reliable improvement on the ReQoL-20 from baseline (weeks 0-1) to post-intervention (weeks 7-8) will be compared against the following progression criterion to provide a preliminary indicator of effectiveness: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Baseline (weeks 0-1) and post-intervention (weeks 7-8)

Secondary outcomes

  1. Proportion of participants showing reliable improvement on the ReQoL-20 from baseline (weeks 0-1) to follow-up (weeks 11-12)

    The ReQoL-20 contains 20 items measuring quality of life, with higher scores indicating greater quality of life. The proportion of participants showing reliable improvement on the ReQoL-20 from baseline (weeks 0-1) to follow-up (weeks 11-12) will be compared against the following progression criterion to provide a preliminary indicator of effectiveness: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Baseline (weeks 0-1) and follow-up (weeks 11-12)

  2. Proportion of participants showing reliable improvement on the DIALOG from baseline (weeks 0-1) to post-intervention (weeks 7-8)

    The DIALOG scale contains 11 items measuring quality of life and treatment satisfaction, with higher scores indicating greater satisfaction. The proportion of participants showing reliable improvement on the DIALOG from baseline (weeks 0-1) to post-intervention (weeks 7-8) will be compared against the following progression criterion to provide a preliminary indicator of effectiveness: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Baseline (weeks 0-1) and post-intervention (weeks 7-8)

  3. Proportion of participants showing reliable improvement on the DIALOG from baseline (weeks 0-1) to follow-up (weeks 11-12)

    The DIALOG scale contains 11 items measuring quality of life and treatment satisfaction, with higher scores indicating greater satisfaction. The proportion of participants showing reliable improvement on the DIALOG from baseline (weeks 0-1) to follow-up (weeks 11-12) will be compared against the following progression criterion to provide a preliminary indicator of effectiveness: Green: ≥75%; Amber: ≥50%; Red: \<50%

    Time frame: Baseline (weeks 0-1) and follow-up (weeks 11 to 12)

  4. Change in average level of daily ratings from baseline (weeks 0-1) to post-intervention (weeks 7-8)

    Brief daily wellbeing ratings (e.g. 'rate your wellbeing on a scale of 0-10') will be collected throughout all phases (baseline, intervention, follow-up) to provide additional time-linked data to evaluate intervention efficacy

    Time frame: Baseline (weeks 0-1) to post-intervention (weeks 7-8)

  5. Change in average level of daily ratings from baseline (weeks 0-1) to follow-up (weeks 11-12)

    Brief daily wellbeing ratings (e.g. 'rate your wellbeing on a scale of 0-10') will be collected throughout all phases (baseline, intervention, follow-up) to provide additional time-linked data to evaluate intervention efficacy

    Time frame: Baseline (weeks 0-1) to follow-up (weeks 11-12)

  6. Qualitative data from follow-up interviews with participants

    An interview of up to an hour will be conducted with participants at the end of the follow-up phase to explore their experiences of using the workbook

    Time frame: Weeks 11-12

07

Study locations

1 of 1 sites recruiting
  • Kent and Medway Mental Health NHS Trust
    Maidstone, ME16 9PH, United Kingdom
    Recruiting
08

References and documents

Publications

  • Toudal, M., & Attwood, T. (2024). Energy accounting: Stress management and mental health monitoring for autism and related conditions. Jessica Kingsley Publishers.

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves extensive data collection from a small number of participants, which may increase the risk of participant identification.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 6 months is below that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 5, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07630376
Lead sponsor
Canterbury Christ Church University
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
Sep 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Kirsten Mann
Contact
k.mann2949@canterbury.ac.uk
+44 (0) 333 011 7101
Fergal Jones
Contact
fergal.jones@canterbury.ac.uk
+44 (0) 1227 927110

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion